Pirfenidone
Top View
- Pirfenidone in Idiopathic Pulmonary Fibrosis
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
- Possible Value of Antifibrotic Drugs in Patients with Progressive Fibrosing
- FLASH NOTE Vicore Pharma Holding AB (VICO-SE) OUTPERFORM Scleroderma the Second Indication for VP01 (C21) Target Price SEK42.00 Current Price SEK16.65
- Fibroblast-Enriched Endoplasmic Reticulum Protein TXNDC5 Promotes Pulmonary fibrosis by Augmenting Tgfβ Signaling Through TGFBR1 Stabilization
- Design and Rationale of Randomized, Double-Blind Trial of the Efficacy and Safety of Pirfenidone in Patients with Fibrotic Hypersensitivity Pneumonitis
- No Relevant Pharmacokinetic Drug-Drug Interaction Between Nintedanib and Pirfenidone
- Role and New Insights of Pirfenidone in Pulmonary Fibrotic Diseases
- Zāļu Patēriņa Statistika Statistics on Medicines Consumption
- Efficacy of Combination Therapy with Pirfenidone and Low-Dose
- Pirfenidone (Esbriet)
- Antifibrotic for Treatment of Idiopathic Pulmonary Fibrosis
- Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
- Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
- Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment
- Reimbursement Criteria for Frequently Requested Drugs
- Extract from the Clinical Evaluation Report for Pirfenidone